JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY) ›› 2014, Vol. 28 ›› Issue (5): 58-61.doi: 10.6040/j.issn.1673-3770.0.2014.075

Previous Articles     Next Articles

Anti VEGF drugs(lucentis) to treat different courses of wet age-related maculardegeneration (62 cases report)

GONG Bin1, FAN Chuan-feng2, WANG Yu2   

  1. 1. Weifang Medical University, Weifang 261031, Shandong, China;
    2. The Second People's Hospital of Jinan City, Jinan 250001, Shandong, China
  • Received:2014-03-03 Published:2014-10-16

PDF (PC)

768

Abstract: Objective To observe the effectiveness of lucentise, an anti- VEGF drug, in the treatment of different courses of wet age-related macular degeneration. Methods 62 cases of wet age-related macular degeneration, including 62 eyes, enrolled into the study. According to the courses of disease, 32 eyes were divided into group A (<6 months) and the other 30 eyes in group B (6-12 months). All the patients received intravitreal injection of ranibizumab (0.5 mg)once a month for 3 consecutive months. At the end of each month, assessment were made to determine whether the next injection was necessary. In a 12-month follow-up,FFA examination was performed every three months. For group A, the average number of letters on ETDRS visual acuity chart was (52.36±8.62), and the average CRT was (334.62±50.26) μm. The corresponding results for Group B were (36.41±6.73) and (368.37±40.52) μm. Visual acuity before and after treatment were observed. The number of letters, macular retinal thickness (CRT) and the injection times between the two groups were compared. Results In group A, 3,6,12 months after the first injection,the improvements of the number of letters in ETDRS eye chart were 16.82 ± 3.56,17.33±3.47 and 15.72±4.38, respectively, compared to 9.23±2.51,10.22±3.46 and 8.34±3.51 in group B (t=9.643,8.074,7.290; P<0.05). The decrease of CRT at 3, 6, 12 months after the first injection were 175.86±55.23 μm, 168.75±46.38 μm and 173.58±35.63 μm in group A,compared to 102.34±32.31 μm, 93.76±28.73 μm and 89.65±27.82 μm in group B (t=6.342,7.593,10.291; P<0.05). In the first year of follow-up, the patients in group A were injected 4.6±1.7 times on average, while the number in group B were 6.8±2.2 times (t=4.422, P<0.05). Conclusion Anti-VEGF drugs (lucentise) demonstrates better clinical results on visual acuity improvement and decrease of CRT thickness for wet age-related macular degeneration patients with duration less than six months than those with duration between six to twelve months. Early application of lucentise injection can reduce the injection times and cost for the treatment.

Key words: Macular degeneration/treatment, Choroidal neovascularization, Antibody, Lucentis

CLC Number: 

  • R774.5
[1] Nowak J Z.Age-related macular degeneration (AMD): pathogenesis and therapy[J]. Pharmacol Rep, 2006, 58(3):353-363.
[2] 刘家琦,李凤鸣.实用眼科学[M].北京：人民卫生出版社,2010：445-447.
[3] Ferrara N. Vascular endothelial growth factor: basic science and clinical progress[J]. EndocrRev, 2004, 25(4):581-611.
[4] Lalwani G A, Rosenfeld P J, Fung A E, et al. A variable-dosing regimen with intravitreal rannibizumab for nevovascular age-related macular degeneration:year 2 of the PrONTO Study[J]. Am J Ophthalmol, 2009, 148(1):43-58.
[5] Li X X, Hu Y H, Sun X, et al. Bevacizumab for neovascular age related macular degeneration in China[J]. Ophthalmology, 2012, 119(10):2087-2093.
[6] Machalińska A, Karczewicz D. Role of complement system in the pathogenesis of AMD[J]. Klin Oczna, 2009, 111(10-12):384-387.
[7] Potter M J, Szabo S M. One-year outcomes after photodynamic therapy in patients with age-related macular degeneration with poor baseline visual acuity[J]. Graefes Arch Clin Exp Ophthalmol, 2006, 244(8)：1026-1028.
[8] 戴虹,喻晓兵,龙力,等.抗血管内皮生长因子单克隆抗体ranibizumab治疗渗出型老年性黄斑变性方案的探讨[J].中华眼底病杂志,2010,26(1)：9-12. DAI Hong, YU Xiaobing, LONG Li, et al. Intravitreal Ranibizumab regimens for exudative aged-related macular degeneration[J]. Chin J Ocular Fundus Dis, 2010, 26(1):9-12.
[9] 李晓陵,何守志,王炜,等.抗血管内皮生长因子单克隆抗体ranibizumab治疗渗出型老年性黄斑变性的一年疗效观察[J].中华眼底病杂志,2011,27(6):515-519. LI Xiaoling, HE Shouzhi, WANG Wei, et al. Clinical observation of intravitreal injection of ranibizumab for 12 consecutive months treating exudative agerelated macular degeneration[J]. Chin J Ocular Fundus Dis, 2011,27 (6): 515-519.
[1] CHEN Xingxue, ZHANG Guangling, WU Tianyi, WANG Weiwei, SUN Zhanwei, LI Shichao, WANG Guangke. Analysis of anti-IL-4Rα monoclonal antibody and endoscopic sinus surgery in the treatment of eosinophilic chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 43-54.
[2] WU Lili, QU Yi. Application of optical tomography angiography and artificial intelligence in choroidal neovascularization secondary to pathologic myopia [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(2): 144-149.
[3] LI Wanyu, GU Xuejun. Anti-neutrophil cytoplasmic antibody associated vasculitis complicated with scleritis and cataract: a case study and literature review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 149-152.
[4] CHU Baorui, QU Yi. Preparation of siIKKβ loaded lipid nanoparticles and assessment of their effect on repolarization of macrophages [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(2): 91-97.
[5] ZHONG Jiake, WANG Baiyang, YI Haijin. Granulomatosis with polyangiitis with initial otological symptoms combined with a nasopharynx lesion: a case report with literature review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(1): 6-14.
[6] ZHANG Taoran, WANG Wei, LI Mingming, HUANG Yingxiang. Subfoveal choroidal thickness changes following intravitreal ranibizumab treatment in choroidal neovascularization due to pathological myopia [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 68-71.
[7] . Diagnosis and treatment of choroidal neovascularization in pathologic myopia [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(5): 157-162.
[8] HU Yabin, ZHENG Yan, ZHANG Jing, WANG Yan, ZHANG Qiulu, LIU Jing, XU Wen, ZHAI Changbin,. Detection of four infection indicators in 4 630 patients before refractive surgery [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(2): 53-56.
[9] ZHANG Ying-chun, DU Xiang-ge, YAN Xin, WANG Cui, ZHAO Bo-jun. Effect of nicotine on human RPE cells and HUVECs [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(2): 74-80.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd